Group 1 - The company has not declared any cash dividends or bonus shares during the reporting period [3] - The company received several approvals from the National Medical Products Administration for its products, including sodium hyaluronate eye drops and antiviral tablets [5] - The company held its eighth board meeting on August 14, 2025, where various reports and proposals were approved [40][41] Group 2 - The company reported a total fundraising amount of RMB 455.53 million from its initial public offering, with a net amount of RMB 390.93 million after expenses [27][28] - The company has established a fundraising management system to ensure compliance with regulations and protect investor interests [30] - As of June 30, 2025, the company has used RMB 44.55 million of its excess fundraising to permanently supplement its working capital [33][35] Group 3 - The company plans to hold its first extraordinary general meeting of 2025 on September 2, 2025, to discuss various proposals [8][52] - The meeting will allow shareholders to vote both in person and online, ensuring accessibility for all stakeholders [9][10] - The company has made amendments to its internal management systems to enhance operational efficiency and compliance with legal requirements [7][50]

Core Points - The report summarizes the financial performance and operational status of Jilin Xidian Pharmaceutical Technology Development Co., Ltd. for the first half of 2025, highlighting a slight decrease in revenue but an increase in net profit [1][2]. Financial Performance - Operating revenue for the reporting period was CNY 128,311,809.27, a decrease of 0.51% compared to the same period last year [1]. - Net profit attributable to shareholders was CNY 24,944,585.08, reflecting a growth of 2.02% year-on-year [1]. - Net cash flow from operating activities increased by 3.49% to CNY 33,713,141.57 [1]. - Basic earnings per share rose by 7.77% to CNY 0.3261, while diluted earnings per share increased by 5.43% to CNY 0.3261 [1]. - The weighted average return on equity was 2.73%, up from 2.56% in the previous year [1]. Asset and Equity Status - Total assets at the end of the reporting period were CNY 1,055,706,506.89, a decrease of 0.65% from the previous year [1]. - Net assets attributable to shareholders increased by 0.56% to CNY 910,831,590.25 [1]. Shareholder Information - The largest shareholder, Zhang Jun, holds 25.66% of the shares, amounting to 19,627,034 shares [2]. - Other significant shareholders include Dingdian Investment Management (7.86%) and Zhuhai Hengqin Yanhe Health Technology (4.83%) [2][3]. - The report indicates that there are no changes in the controlling shareholder or actual controller during the reporting period [4]. Important Events - The company received approval for several drug applications, including sodium hyaluronate eye drops and antiviral tablets, which may enhance its product portfolio and market position [6].

Core Viewpoint - The company, Jilin Xidian Pharmaceutical Technology Development Co., Ltd., has released its annual report for 2024, highlighting its financial performance, business operations, and future development plans. The report indicates a focus on the research, production, and sales of chemical raw materials and formulations, particularly in the fields of iron supplementation and psychiatric medications [1][5]. Company Overview - The company primarily engages in the research, production, and sales of chemical raw materials and formulations, with a strong emphasis on iron supplementation, treatment of circulatory disorders, and psychiatric medications [5]. - As of the end of the reporting period, the company holds 25 registered formulation varieties (32 specifications) and 16 registered raw material drug approvals, focusing on anti-anemia, circulatory disorder treatments, and psychiatric medications [5]. Financial Highlights - The company has received a standard unqualified audit opinion from Rongcheng Accounting Firm for the financial report of the reporting period [3]. - The board of directors approved a profit distribution plan, proposing a cash dividend of 2.60 yuan per 10 shares (including tax), with no stock bonus or capital reserve transfer [4][9]. Shareholder Information - The company has no preferred shareholders and has disclosed the shareholding structure, including the top 10 shareholders [7][8]. Recent Developments - The company has received several approvals for new drug applications, including sodium hyaluronate eye drops and other formulations, indicating ongoing product development and regulatory compliance [8][65]. - The company has also obtained a patent for the application of rhizoma smilacis in preparing drugs for treating lymphatic reflux disorders [10][67]. Governance and Compliance - The company’s board and supervisory committee have ensured that the annual report and its summary are accurate and complete, with no misleading statements or omissions [11][18]. - The company has appointed Rongcheng Accounting Firm as its auditor for the year 2025, following a thorough review of the firm’s qualifications and capabilities [42][56].